Biogen Marginally Outbid Another Big Pharma For $7.3bn Reata Acquisition
Unnamed Firm Was Likely Sanofi
The US firm’s multi-billion dollar buyout of the rare disease biotech Reata was not so straightforward according to a recent security filing that detailed a back-and-forth bidding process between Biogen and a rival company that initiated first contact, believed to be Sanofi.
